A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands

被引：1

作者：

Michels, Renee E. ^{[1
]}

Peters, Michel L. ^{[1
]}

Schiffers, Krijn Mh ^{[2
,3
]}

Bouma, Paul A. ^{[4
]}

Hengstman, Gerald I. D. ^{[5
]}

van Munster, Caspar E. P. ^{[6
]}

Zeinstra, Esther ^{[7
]}

De Voer, Gert ^{[2
,3
]}

Krol, Marieke ^{[1
]}

机构：

[1] IQVIA, Dept Real World & Analyt Solut, Herikerbergweg 314, NL-1101 CT Amsterdam, Netherlands

[2] Merck BV, Darmstadt, Germany

[3] Tupolevlaan 61, NL-1119 NW Schiphol Rijk, Netherlands

[4] Tergooi Ziekenhuis, Dept Neurol, van Riebeeckweg 212, NL-1213 XZ Hilversum, Netherlands

[5] Catharina Hosp, Dept Neurol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands

[6] Amphia Ziekenhuis, Dept Neurol, Molengracht 21, NL-4818 CK Breda, Netherlands

[7] Isala, Dept Neurol, Hoogeveenseweg 38, NL-7943 KA Meppel, Netherlands

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 10卷 / 02期

关键词：

Delphi panel; disease modifying therapy; multiple sclerosis; reimbursement; relapsing remitting multiple sclerosis; the Netherlands; treatment pathway; CELLS; MS;

D O I：

10.2217/cer-2020-0140

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To gain insight into current treatment and barriers to optimal treatment for high disease activity relapsing remitting multiple sclerosis (MS) in the Netherlands. Materials & methods: A two-round Delphi panel using an online questionnaire was conducted. Seven MS neurologists from diverse locations in the Netherlands were invited to participate. Result: Out of the seven MS neurologists, five completed both questionnaire rounds. Conclusion: Effectiveness and side effects along with patient's lesion load were the most important factors for choosing a disease modifying therapy (DMTs). Respondents felt restricted to optimally treat their patients due to reimbursement restrictions for certain disease modifying therapies, although agreed that satisfactory treatment options are currently available. The answers show consensus between the participating MS neurologists with high certainty of answers.

引用

页码：93 / 100

页数：8

共 16 条

[11] Defining the clinical course of multiple sclerosis The 2013 revisions [J].

Lublin, Fred D. ;

Reingold, Stephen C. ;

Cohen, Jeffrey A. ;

Cutter, Gary R. ;

Sorensen, Per Soelberg ;

Thompson, Alan J. ;

Wolinsky, Jerry S. ;

Balcer, Laura J. ;

Banwell, Brenda ;

Barkhof, Frederik ;

Bebo, Bruce, Jr. ;

Calabresi, Peter A. ;

Clanet, Michel ;

Comi, Giancarlo ;

Fox, Robert J. ;

Freedman, Mark S. ;

Goodman, Andrew D. ;

Inglese, Matilde ;

Kappos, Ludwig ;

Kieseier, Bernd C. ;

Lincoln, John A. ;

Lubetzki, Catherine ;

Miller, Aaron E. ;

Montalban, Xavier ;

O'Connor, Paul W. ;

Petkau, John ;

Pozzilli, Carlo ;

Rudick, Richard A. ;

Sormani, Maria Pia ;

Stueve, Olaf ;

Waubant, Emmanuelle ;

Polman, Chris H. .

NEUROLOGY, 2014, 83 (03) :278-286

[12] The Delphi technique: myths and realities [J].

Powell, C .

JOURNAL OF ADVANCED NURSING, 2003, 41 (04) :376-382

[13] Using the Delphi technique in economic evaluation: time to revisit the oracle? [J].

Simoens, S. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (06) :519-522

[14]

Zorginstituut Nederland, 2014, HERB DUID NAT TYS

[15]

Zorginstituut Nederland, 2018, GVS BEOORD CLADR MAV

[16]

Zorginstituut Nederland, 2016, WIJZ BIJL 2 VOORW FI

← 1 2 →